Life Science Today

Originally Published as The Niche Podcast

We dive deep into Alzheimer’s, Regeneron execs might be overpaid, a merger in clinical research, and the FDA issues a Class 1 recall

Sponsors
https://www.thescopemethod.com

Story References
https://tinyurl.com/Niche-054-1
https://tinyurl.com/Niche-054-2
https://tinyurl.com/Niche-054-3
https://tinyurl.com/Niche-054-4
https://tinyurl.com/Niche-054-5

 Music by Luke Goodson
https://www.soundcloud.com/lukegoodson

Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.

Originally Published as The Niche Podcast

Pending FDA approvals, expanded FDA approvals, new FDA approvals, and a lawsuit about FDA approvals.

Sponsors
https://www.thescopemethod.com

Story References
https://tinyurl.com/Niche-053-1
https://tinyurl.com/Niche-053-2
https://tinyurl.com/Niche-053-3
https://tinyurl.com/Niche-053-4
https://tinyurl.com/Niche-053-5
https://tinyurl.com/Niche-053-6

Music by Luke Goodson
https://www.soundcloud.com/lukegoodson

Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.

Originally Published as The Niche Podcast

M&A Speed Bumps, “Normal” IPO but not approach, two updates, and FDA gives nod to menstrual bleeding, prostate cancer, and COVID19 monoclonal antibodies.

Sponsors
https://www.thescopemethod.com

Story References
https://tinyurl.com/Niche-052-1
https://tinyurl.com/Niche-052-2
https://tinyurl.com/Niche-052-3a
https://tinyurl.com/Niche-052-4
https://tinyurl.com/Niche-052-5
https://tinyurl.com/Niche-052-6
https://tinyurl.com/Niche-052-7

Music by Luke Goodson
https://www.soundcloud.com/lukegoodson

Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.

Originally Published as The Niche Podcast

Oncology on the move, an industry report looking at broader trends, good news in Alzheimer’s, and another niche oncology therapy approved.

Sponsors
https://www.thescopemethod.com

Story References
https://tinyurl.com/Niche-051-1
https://tinyurl.com/Niche-051-2
https://tinyurl.com/Niche-051-3
https://tinyurl.com/Niche-051-4
https://tinyurl.com/Niche-051-5

Music by Luke Goodson
https://www.soundcloud.com/lukegoodson

Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.

Originally Published as The Niche Podcast

Two FDA approvals, cellulite and tattoos, Ginkgo pulls in $2.5B, and Caris massive growth equity for oncology testing.

Sponsors
https://www.thescopemethod.com

Story References
https://tinyurl.com/Niche-50-1
https://tinyurl.com/Niche-50-2
https://tinyurl.com/Niche-50-3
https://tinyurl.com/Niche-50-4
https://tinyurl.com/Niche-50-5
https://tinyurl.com/Niche-50-6
https://tinyurl.com/Niche-50-7

Music by Luke Goodson
https://www.soundcloud.com/lukegoodson

Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.

Originally Published as The Niche Podcast

Critical intellectual property move by Biden-Harris, Pfizer goes for full approval, SPAC 1, SPAC 2, Regeneron drops big numbers, and an IPO gets punted.

Sponsors
https://www.thescopemethod.com

Story References
https://tinyurl.com/Niche-049-1
https://tinyurl.com/Niche-049-2
https://tinyurl.com/Niche-049-3
https://tinyurl.com/Niche-049-4
https://tinyurl.com/Niche-049-5
https://tinyurl.com/Niche-049-6

Music by Luke Goodson
https://www.soundcloud.com/lukegoodson

 The Niche Podcast brings you interviews with industry experts and top stories from last week in biotech, pharma, clinical research, and the life science industries. You can expect highlights about new technologies, biotech and pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to IPOs. The Niche also tries to highlight trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed, move through clinical trials, and become approved by regulatory agencies. It’s news, with a dash of perspective, focused on these Niche industries.

Originally Published as The Niche Podcast

Welcome to a monthly bonus episode. I sat down with Dr. Amir Kalali, the co-chair of the Decentralized Trials & Research Alliance (DTRA) – a clinical research coalition of the most influential companies in the field to talk about decentralized research and collaborating for our success as an industry.

2:35 – From CRO to CNS Summit 
10:30 – Ramping up DTRA 
12:29 – The Ramp of Decentralized Trials 
15:50 – What will stick after the pandemic?
19:28 – How different are decentralized trials really? 
22:42 – Technology traps and Hybrid Trials
25:12 – How are trust networks changing with decentralized trials? 
29:09 – What is the roll of DTRA in the industry? 
33:28 – Ecosystems are interconnected, how can we partner within the clinical research/pharma ecosystem?
36:10 – What is the future of the DTRA? 

Subscribe@
https://thenichepod.com

Sponsors
https://www.thescopemethod.com

Story References
https://cnssummit.org
https://dtra.org
https://www.linkedin.com/in/amirkalali/

 The Niche Podcast brings you interviews with industry experts and top stories from last week in biotech, pharma, clinical research, and the life science industries. You can expect highlights about new technologies, biotech and pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to IPOs. The Niche also tries to highlight trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed, move through clinical trials, and become approved by regulatory agencies. It’s news, with a dash of perspective, focused on these Niche industries.

Originally Published as The Niche Podcast

The FDA slaps wrists and takes names, Farxiga expands FDA approval, BioVie makes cash-light acquisition, Pfizer targets fungus, and one IPO down, another to go.

Sponsors
https://www.thescopemethod.com


Story References
https://tinyurl.com/Niche-047-1
https://tinyurl.com/Niche-047-2
https://tinyurl.com/Niche-047-3
https://tinyurl.com/Niche-047-4
https://tinyurl.com/Niche-047-5
https://tinyurl.com/Niche-047-6

Music by Luke Goodson
https://www.soundcloud.com/lukegoodson

Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.

Originally Published as The Niche Podcast

Billion-dollar amendments, billion-dollar funds, GSK gets oncology nod from FDA, and two stories in clinical research.


Sponsors
https://www.thescopemethod.com


Story References
https://tinyurl.com/Niche-046-1
https://tinyurl.com/Niche-046-2
https://tinyurl.com/Niche-046-3
https://tinyurl.com/Niche-046-4
https://tinyurl.com/Niche-046-5


Music by Luke Goodson
https://www.soundcloud.com/lukegoodson

Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.

Originally Published as The Niche Podcast

Massive acquisitions in the CRO space, Trodelvy 2x, diagnostic acquisitions, Merck closes COVID vaccine program, Xolair get’s self-injection nod, and tiny robots go for massive SPAC.
 

Sponsors
https://www.thescopemethod.com


Story References
https://tinyurl.com/Niche-045-1
https://tinyurl.com/Niche-045-2
https://tinyurl.com/Niche-045-3
https://tinyurl.com/Niche-045-4
https://tinyurl.com/Niche-045-5
https://tinyurl.com/Niche-045-6


Music by Luke Goodson
https://www.soundcloud.com/lukegoodson

Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.